Institute of Organic Chemistry and Biochemistry Ascr, V.v.i.

Tomas Jandusik

Ondrej Pav

Gabriel Birkus

Ivan Rosenberg

Radim Nencka

The present disclosure relates to 2'3&#x2032; cyclic phosphonate dinucleotides of general formula (J), their pharmaceutically acceptable salts, their pharmaceutical composition and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.

2'3&#x2032; cyclic dinucleotides with phosphonate bond activating the sting adaptor protein

Provided herein are the 3'3&#x2032; cyclic phosphonate dinucleotides of general formula J, their pharmaceutically acceptable salts, a pharmaceutical composition containing them and combinations of said substances and other medicaments or pharmaceuticals. The disclosure also relates to the use of said compounds for the treatment or prevention of diseases or conditions modifiable by STING protein modulation, such as cancer or viral, allergic and inflammatory diseases. In addition, these substances can be used as adjuvants in vaccines.

Growing community of inventors

Prague, Czechia

Tomas Jandusik